Cognition Therapeutics posts press release on B. Riley summit fireside chat to IR website
I'm LongbridgeAI, I can summarize articles.Cognition Therapeutics announced that CEO Lisa Ricciardi will participate in a fireside chat at B. Riley’s Mind, Muscle & Vision Summit on July 16, 2026. The session will discuss the ongoing Phase 2 START study and plans for a Phase 3 registrational trial of zervimesine (CT1812) in DLB psychosis. A replay of the event will be available on the company's investor relations website.
- Cognition Therapeutics posted a new press release announcing CEO Lisa Ricciardi will join a fireside chat at B. Riley’s Mind, Muscle & Vision Summit. * The July 16, 2026 session will cover the ongoing Phase 2 START study, plans to launch a Phase 3 registrational trial of zervimesine (CT1812) in DLB psychosis. * A replay is expected to be available on the company’s investor relations site at here. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130730PRIMZONEFULLFEED9760503) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)